Topline results from HighTide Therapeutics’s HTD1801 NASH study.

Topline results from HighTide Therapeutics’s HTD1801 NASH study.

Results showed a statistical significant reduction in liver fat in patients with NASH and diabetes. Our contribution to this important study is what makes us proud of what we do!
https://www.businesswire.com/news/home/20200507005019/en/HighTide-Therapeutics-Announces-Positive-Topline-Results-Phase

/ Uncategorized

Share the Post

Our Response to COVID-19
X